RESUMO
OBJECTIVE: To measure symptomatic and functional remission in patients treated with risperidone long-acting injectable (RLAI). METHODS: Stable patients with psychotic disorders requiring medication change were switched to open-label RLAI in the switch to risperidone microspheres (StoRMi) trial. In this post-hoc analysis of the trial extension, follow-up was